35.15
+15.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immunovant
From its filings with the US Securities and Exchange Commission
Immunovant is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IMVT. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 March 2026, it reported a net loss of $505.6m. At that date it held total assets of $957.0m and shareholders' equity of $852.6m.
Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.
We believe that FcRn inhibition has broad therapeutic and commercial potential to address pathogenic IgG-mediated autoimmune diseases in several therapeutic areas, including but not limited to, endocrinology, neurology, rheumatology and dermatology. Third-party estimates suggest over four million patients in the United States and Europe could benefit from anti-FcRn treatments across more than 20 indications that have been publicly announced for research and development by multiple companies, with two indications that are already approved and launched quickly reaching multi-billions of dollars in global annual sales.
Quoted from its 10-K, filed 20 May 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 May 2019
- Employees
- 315
- Website
- immunovant.com ↗
- Head office
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Frank TortiExecutive Chairman of the Board, since 2019$4.9m
- Dr. Eric VenkerChief Executive Officer, Director, since 2020$55,000
- Mr. Tiago GiraoChief Financial Officer
- Ms. Melanie GloriaChief Operating Officer$5.6m
- Dr. Jay StoutChief Technology Officer$4.0m
- Dr. Michael GeffnerChief Medical Officer$4.1m
- Mr. Christopher Van TuylChief Legal Officer, Corporate Secretary$5.9m
- Mr. Andrew FromkinDirector$530,036
- Mr. Jacob BauerIndependent Director
- Mr. Douglas HughesIndependent Director$520,036
- Dr. Atul PandeIndependent Director$517,536
- Mr. Robert SusmanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 25
- Social
- 42
- Governance
- 9
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company focuses on autoimmune disease treatments with a pipeline including batoclimab and IMVT-1402.
- Products target FcRn receptor with potential to reduce IgG antibodies causing inflammation.
- Headquartered in New York City with 315 employees as per company data.
Weaknesses
- Source description states 164 employees, conflicting with company data of 315 employees.
- IPO date provided as 2019-05-14 matches company data.
- Product details in source description may not reflect current pipeline status.
Opportunities
- Development of batoclimab for multiple autoimmune conditions including MG, TED, CIDP, and GD.
- IMVT-1402 shows potential in nonclinical studies for reducing IgG antibody levels.
- Subcutaneous injection format with small volumes and 27-gauge needle may improve patient compliance.
Threats
- Source description may contain untrusted facts conflicting with company data.
- Clinical-stage biopharmaceutical company faces high development risks.
- Biotechnology sector competition could impact product development timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.